An integrated biochemical and genetic approach will be used to investigate the mechanism, specificity, intracellular targeting and multiple functions of the human type I topoisomerase (topo I). With the availability of milligram quantities of pure topo I and high titer affinity purified antibodies against the protein, a number of biologically important issues can be investigated.
The specific aims are (i) to produce sufficient quantities of different forms of pure topo I with and without bound duplex oligonucleotides for crystallographic studies, (ii) to use a mutant form of topo I containing a substitution of phenylalanine for the active site tyrosine (Y723F mutant) to study how DNA sequence and DNA topology affect the binding of DNA by the protein, (iii) to use the ligation-mediated polymerase chain reaction to avoid the use of camptothecin in identifying topo I break sites associated with transcription and DNA replication in human cells, (iv) to determine the effects of overexpressing the wild type and Y723F mutant forms of topo I in human cells, and (v) to isolate cDNAs which encode proteins that specifically interact with topo I. The biochemical and crystallographic studies will elucidate the details of the catalytic mechanism of topo I as well as provide an understanding of the basis for the inhibitory effects of the anti-cancer drug, camptothecin. These studies will also clarify the relationship between the sequence requirements for the binding of the enzyme to DNA with the sequence requirements for topo I- mediated breakage of DNA after addition of denaturants. The overexpression studies in combination with the search for interacting partners of the protein should provide important insights into how the topo I associates with other proteins in the cell to provide the swivels required for DNA replication and transcription. Studies which address the involvement of topo I in illegitimate recombination may reveal a role for the enzyme in the genetic instability of cancer cells, especially colon carcinoma cells which exhibit elevated levels of topo I.

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Research Project (R01)
Project #
5R01GM049156-04
Application #
2415190
Study Section
Biochemistry Study Section (BIO)
Project Start
1994-05-01
Project End
1998-05-31
Budget Start
1997-05-01
Budget End
1998-05-31
Support Year
4
Fiscal Year
1997
Total Cost
Indirect Cost
Name
University of Washington
Department
Microbiology/Immun/Virology
Type
Schools of Medicine
DUNS #
135646524
City
Seattle
State
WA
Country
United States
Zip Code
98195
Interthal, Heidrun; Champoux, James J (2011) Effects of DNA and protein size on substrate cleavage by human tyrosyl-DNA phosphodiesterase 1. Biochem J 436:559-66
Sandler, Irwin; Ayers, Tim S; Tein, Jenn-Yun et al. (2010) Six-year follow-up of a preventive intervention for parentally bereaved youths: a randomized controlled trial. Arch Pediatr Adolesc Med 164:907-14
Yang, Zheng; Carey, James F; Champoux, James J (2009) Mutational analysis of the preferential binding of human topoisomerase I to supercoiled DNA. FEBS J 276:5906-19
Yang, Zheng; Champoux, James J (2009) Assays for the preferential binding of human topoisomerase I to supercoiled DNA. Methods Mol Biol 582:49-57
Kim, Hyeongnam; Cardellina 2nd, John H; Akee, Rhone et al. (2008) Arylstibonic acids: novel inhibitors and activators of human topoisomerase IB. Bioorg Chem 36:190-7
Hirano, Ryuki; Interthal, Heidrun; Huang, Cheng et al. (2007) Spinocerebellar ataxia with axonal neuropathy: consequence of a Tdp1 recessive neomorphic mutation? EMBO J 26:4732-43
Davies, Douglas R; Mushtaq, Adeel; Interthal, Heidrun et al. (2006) The structure of the transition state of the heterodimeric topoisomerase I of Leishmania donovani as a vanadate complex with nicked DNA. J Mol Biol 357:1202-10
Interthal, Heidrun; Chen, Hong Jing; Champoux, James J (2005) Human Tdp1 cleaves a broad spectrum of substrates, including phosphoamide linkages. J Biol Chem 280:36518-28
Interthal, Heidrun; Chen, Hong Jing; Kehl-Fie, Thomas E et al. (2005) SCAN1 mutant Tdp1 accumulates the enzyme--DNA intermediate and causes camptothecin hypersensitivity. EMBO J 24:2224-33
Leppard, John B; Champoux, James J (2005) Human DNA topoisomerase I: relaxation, roles, and damage control. Chromosoma 114:75-85

Showing the most recent 10 out of 36 publications